Literature DB >> 17853293

Lamotrigine in motor and mood symptoms of Huntington's disease.

Yu-Chih Shen1.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterized by midlife onset, progressive course and a combination of motor, cognitive and psychiatric symptoms. Since dysregulation of the glutamate/calcium signalling pathway is beginning to emerge as a potential cause of neuron degeneration, antagonists of glutamate pathways such as lamotrigine, may have beneficial value for treatment of HD. We describe the use of lamotrigine in the treatment of an HD patient with motor abnormality (choreoathetoidic movements) complicated by psychiatric abnormalities (depression, severe mood swing and recurrent high risk of suicidal attempts). The patient's depression, severe mood swing and choreoathetoidic movements significantly improved with 300 mg/day of lamotrigine. Experience from our patient suggests that lamotrigine might be effective in treating HD patients with motor and mood symptoms. Further controlled studies are warranted to confirm its efficacy in patients of this type.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17853293     DOI: 10.1080/15622970701332520

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  5 in total

Review 1.  Antiseizure Drugs and Movement Disorders.

Authors:  Michel Sáenz-Farret; Marina A J Tijssen; Dawn Eliashiv; Robert S Fisher; Kapil Sethi; Alfonso Fasano
Journal:  CNS Drugs       Date:  2022-07-21       Impact factor: 6.497

Review 2.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

3.  Treatment of Irritability in Huntington's Disease.

Authors:  Erik van Duijn
Journal:  Curr Treat Options Neurol       Date:  2010-07-10       Impact factor: 3.598

4.  International Guidelines for the Treatment of Huntington's Disease.

Authors:  Anne-Catherine Bachoud-Lévi; Joaquim Ferreira; Renaud Massart; Katia Youssov; Anne Rosser; Monica Busse; David Craufurd; Ralf Reilmann; Giuseppe De Michele; Daniela Rae; Ferdinando Squitieri; Klaus Seppi; Charles Perrine; Clarisse Scherer-Gagou; Olivier Audrey; Christophe Verny; Jean-Marc Burgunder
Journal:  Front Neurol       Date:  2019-07-03       Impact factor: 4.086

5.  Network medicine for disease module identification and drug repurposing with the NeDRex platform.

Authors:  Sepideh Sadegh; James Skelton; Elisa Anastasi; Judith Bernett; David B Blumenthal; Gihanna Galindez; Marisol Salgado-Albarrán; Olga Lazareva; Keith Flanagan; Simon Cockell; Cristian Nogales; Ana I Casas; Harald H H W Schmidt; Jan Baumbach; Anil Wipat; Tim Kacprowski
Journal:  Nat Commun       Date:  2021-11-25       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.